Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Immucell Corp changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 27 | 26 | −1 |
| Shares | 1.28M | 1.28M | −3.97K (−0.3%) |
| Value | $8.08M | $7.87M | −$204.9K (−2.5%) |
New holders (2)
Institutions that held Immucell Corp at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Flagship Harbor Advisors, LLC | 730 | $4.49K | 0.00% |
| Harbour Investments, Inc. | 250 | $1.54K | 0.00% |
Sold out (3)
Institutions that held Immucell Corp at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Citigroup Inc | 170 | $1.10K |
| Barclays PLC | 7 | $44 |
| Royal Bank of Canada | 1 | $0 |